تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | $14.6B | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.4B | $9.6B | $8.7B | $6.0B | $5.8B | $5.7B | $5.5B | $5.0B | $4.7B | $4.5B | $4.1B | $3.6B |
| إجمالي الربح | $4.1B | $3.7B | $3.6B | $3.4B | $3.7B | $5.0B | $5.0B | $3.3B | $3.2B | $3.5B | $3.2B | $2.9B | $2.2B | $2.2B | $2.2B | $2.3B | $2.1B | $2.0B | $1.9B | $1.7B | $1.5B |
| هامش الربح الإجمالي % | 28.0% | 26.8% | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% | 28.1% | 28.0% | 33.2% | 33.0% | 33.5% | 36.6% | 38.3% | 39.7% | 41.0% | 41.9% | 42.0% | 41.6% | 41.6% | 42.6% |
| الدخل التشغيلي (EBIT) | $1.6B | $1.5B | $1.1B | $726M | $1.4B | $3.0B | $2.4B | $1.3B | $1.3B | $1.4B | $1.3B | $1.0B | $910M | $991M | $1.0B | $948M | $979M | $936M | $843M | $777M | $697M |
| هامش التشغيل % | 11.1% | 10.9% | 8.3% | 6.0% | 12.1% | 23.2% | 17.5% | 11.5% | 11.7% | 13.1% | 13.6% | 11.6% | 15.1% | 17.1% | 18.1% | 17.1% | 19.6% | 19.9% | 18.7% | 19.1% | 19.4% |
| صافي الدخل | $1.0B | $876M | $746M | $418M | $1.3B | $2.4B | $1.6B | $824M | $884M | $1.3B | $732M | $437M | $511M | $574M | $583M | $520M | $558M | $543M | $464M | $477M | $432M |
| هامش الربح الصافي % | 6.9% | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 12.2% | 7.6% | 5.0% | 8.5% | 9.9% | 10.3% | 9.4% | 11.2% | 11.6% | 10.3% | 11.7% | 12.0% |
| EBITDA | — | $2.0B | $1.8B | $1.3B | $2.0B | $3.7B | $3.3B | $2.1B | $2.1B | $1.8B | $1.8B | $1.6B | $1.2B | $1.2B | $1.3B | $1.2B | $1.2B | $1.1B | $1.0B | $990M | $853M |
| ربحية السهم (EPS) | $12.19 | $10.46 | $8.84 | $4.77 | $13.96 | $24.38 | $15.88 | $8.35 | $8.61 | $12.21 | $7.02 | $4.34 | $5.92 | $6.25 | $5.99 | $5.11 | $5.30 | $4.98 | $4.10 | $3.93 | $3.24 |
| الأسهم القائمة (م) | — | 84M | 84M | 88M | 92M | 98M | 98M | 99M | 103M | 104M | 104M | 101M | 86M | 92M | 97M | 102M | 105M | 109M | 113M | 121M | 133M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ LH. /companies/us/LH
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms